Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TACR3 | P29371 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11092397 | 0.98 | APLNR (0.76) | APLNRMEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL783785 | 0.88 | APLNR (1.00) | APLNRMEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL21159301 | 0.87 | APLNR (0.83) | APLNRMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2277593 | 0.85 | APLNR (0.73) | APLNRMEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL6418283 | 0.85 | APLNR (0.73) | APLNRMEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL27163106 | 0.82 | APLNR (0.86) | APLNRMEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL18124510 | 0.82 | BCHE (0.75) | APLNRMEN1KMT2AKDM4EMAPT | |
| SCHEMBL7768853 | 0.82 | APLNR (0.86) | APLNRMEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL8883322 | 0.82 | KDM4E (0.70) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL30004302 | 0.81 | KDM4E (0.61) | APLNRMEN1KMT2AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025074096-A1 | P97 (VCP) ATPASE INHIBITORS | Turbine Simulated Cell Technologies Ltd (GB) | 2025-04-10 | — | — | WO | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2023012153-A1 | VALOSIN-CONTAINING PROTEIN (VCP/P97) INHIBITORS | PHOREMOST LIMITED (GB) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023012153-A1 | VALOSIN-CONTAINING PROTEIN (VCP/P97) INHIBITORS | PHOREMOST LIMITED (GB) | 2023-02-09 | — | — | WO | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
| US-10947263-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200223883-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-16 | — | — | US | disclosed |
| US-20180118679-A1 | N-Methyl Pyrazoles | Prosetta Antiviral ,Inc. | 2018-05-03 | — | — | US | disclosed |
| US-5621103-A | 3-(SUBSTITUTED METHYLAMINOCARBONYL)-1,2,3,4-TETRAHYDRO-(1)BENZOTHIENO(2,3-C) PYRIDINES; ANXIOLYTIC AGENTS; LEARNING ENHANCEMENT | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118679-A1 | N-Methyl Pyrazoles | ZC3HAV1, MAVS, NNMT | APLNR 3849/4885MEN1 1084/4885KMT2A 768/4885 |
| US-10947263-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | APLNR 2575/4885MEN1 1734/4885KMT2A 2144/4885 |
| US-20200223883-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | APLNR 2575/4885MEN1 1734/4885KMT2A 2144/4885 |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | APLNR 2870/4885MEN1 1929/4885KMT2A 2358/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | APLNR 2870/4885MEN1 1929/4885KMT2A 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.